Teva has announced that it has completed its Phase III trials program for its multiple sclerosis treatment Copaxone (copolymer-1 or COP-1). The compound, which is classified as an Orphan Drug in the USA, is intended for use as a treatment for the exacerbating/ remitting form of the disease. It is estimated that there are approximately 100,000 sufferers of this type of MS in the USA and an additional 300,000 in the rest of the world.
COP-1 is a synthetic biochemical substance which is similar in structure to myelin basic protein. The drug is thought to act as a decoy to locally-produced autoimmune antibodies, binds to them and then attaches to and neutralizes the aberrant T-cell lines.
The results of this trial are sufficiently compelling to indicate that the company may be in a position to file a New Drug Application with the US Food and Drug Administration by the end of this year or early next, according to Teva chief executive Eli Hurvitz. Simultaneous applications will also be made in Europe and Israel, he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze